The global Age-Related Molecular Degeneration Market Size is currently valued at US$ 11.28 million in 2023 and is expected to grow at a CAGR of 7%. Because to technology advancements in healthcare, the market is expected to reach US$ 22.19 million by 2033.
Age-Related Molecular Degeneration (AMD) is a prevalent and progressive eye condition that primarily affects older adults. It is characterized by the deterioration of the macula, a small central portion of the retina responsible for sharp, detailed vision. The molecular changes associated with AMD occur due to a combination of genetic and environmental factors. One key molecular mechanism is the accumulation of drusen, yellow deposits made up of lipids, proteins, and other waste materials, beneath the retinal pigment epithelium. These drusen disrupt the normal functioning of the cells in the macula, leading to the death of photoreceptor cells and subsequent vision loss.
Unlock growth potential with industry expertise. Download your market sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16152In addition to drusen accumulation, Age-Related Molecular Degeneration involves chronic inflammation and oxidative stress. These processes trigger the release of reactive oxygen species and inflammatory molecules, which damage retinal cells and impair their ability to function correctly. Over time, this molecular degeneration results in the development of dry Age-Related Molecular Degeneration or, in more severe cases, the growth of abnormal blood vessels beneath the retina, known as wet Age-Related Molecular Degeneration. Understanding the underlying molecular mechanisms of age-related macular degeneration is crucial for developing effective treatments and preventive strategies to alleviate the burden of this sight-threatening condition.
Key Takeaways from the Market Study
The market for Age-Related Molecular Degeneration was assessed at US$ 11.28 billion in 2023.
The Age-Related Molecular Degeneration sector is expected to increase at a 7% CAGR between 2023 and 2033.
The Age-Related Molecular Degeneration market is expected to be worth US$ 22.19 billion by 2033.
The hospital pharmacy segment accounted for the biggest portion of the distribution channel (55%), and this trend is likely to continue during the forecast period.
In terms of Age-Related Molecular Degeneration, China is expected to produce a CAGR of 6.8% by 2033.
“Growing healthcare spending and increase in the prevalence of Age-Related Molecular Degeneration, retinal disorders are expected to radically transform the Age-Related Molecular Degeneration market in the coming years,” comments an analyst at FMI.
Age-Related Molecular Degeneration Market Report Available At a Discounted Price:
https://www.futuremarketinsights.com/request-discount/rep-gb-16152Competitive Landscape
Key Players:
F. Hoffmann-La Roche Ltd.
Novartis AG
Bayer AG
Pfizer Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Amgen Inc.
Biogen
Samsung Bioepis
Ophthotech Corporation
Locked
